Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

A new C9ORF72 mouse model develops mild motor weakness and ALS/FTD-related pathology

Original source

Intrathecal (G4C2)149 delivery in C9orf72-deficient mice yields mild motor dysfunction and ALS/FTD pathological hallmarks.Acta Neuropathol Commun · 18 June 2026 (opens in a new tab)

Compass summarised this from the study's abstract.

Study details

Studied in
Human, Mouse

Related topics

Researchers delivered an adeno-associated virus carrying C9ORF72 repeat sequences into newborn mice, including mice with reduced C9ORF72. The mice developed mild, progressive muscle weakness and several spinal cord changes linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Why this matters

The model may help researchers study how C9ORF72 repeat expansion and reduced C9ORF72 contribute to disease. It was tested in mice and does not change treatment for people with ALS or FTD.

Limitations and context

This was a primary research study in mice, using neonatal intrathecal viral delivery. The resulting disease features were mild, and the findings have not established that the model predicts treatment effects or disease progression in people.

Summarised by Compass 16 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Bibliographic data from PubMed is courtesy of the U.S. National Library of Medicine. Compass does not reproduce source abstracts and may not reflect the most current record.

Relevant to you?